Age is the single greatest risk factor for most causes of morbidity and mortality in humans and their companion animals. As opposed to other model organisms used to study aging, dogs share the human environment, are subject to similar risk factors, receive comparable medical care, and develop many of the same age-related diseases humans do. In this study, 24 middle-aged healthy dogs received either placebo or a non-immunosuppressive dose of rapamycin for 10 weeks. All dogs received clinical and hematological exams before, during, and after the trial and echocardiography before and after the trial. Our results showed no clinical side effects in the rapamycin-treated group compared to dogs receiving the placebo. Echocardiography suggested improvement in both diastolic and systolic age-related measures of heart function (E/A ratio, fractional shortening, and ejection fraction) in the rapamycin-treated dogs. Hematological values remained within the normal range for all parameters studied; however, the mean corpuscular volume (MCV) was decreased in rapamycin-treated dogs. Based on these results, we will test rapamycin on a larger dog cohort for a longer period of time in order to validate its effects on cardiac function and to determine whether it can significantly improve healthspan and reduce mortality in companion dogs.
This is a preview of subscription content, log in to check access
We would like to thank Dr. Karen Kline and Dr. Heidi MacLean for clinical veterinary support. This work was partially supported by the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging (NIH Grant P30AG013280). SU was supported by donations from the Irish Wolfhound Association of New England and the Donner Foundation to the Dog Aging Project. DP and KC received support from NIH Grant R24AG044284.
Compliance with ethical standards
All procedures were approved by the University of Washington Institutional Animal Care and Use Committee (IACUC) under protocol number 4359-02. All of the owners completed a written informed consent prior to their first study-related veterinary visit.
Detweiler DK, Patterson DF (1965) The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 127(1):481–516CrossRefPubMedGoogle Scholar
Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63(23):8451–8460PubMedGoogle Scholar
Fischer KE et al (2015) Health effects of long-term rapamycin treatment: the impact on mouse health of enteric rapamycin treatment from four months of age throughout life. PLoS One 10(5):e0126644CrossRefPubMedPubMedCentralGoogle Scholar
Gamaldo AA, Ferrucci L, Rifkind J, Longo DL, Zonderman AB (2013) Relationship between mean corpuscular volume and cognitive performance in older adults. J Am Geriatr Soc 61(1):84–89CrossRefPubMedPubMedCentralGoogle Scholar
Halloran J et al (2012) Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 223:102–113CrossRefPubMedPubMedCentralGoogle Scholar
Kaeberlein M, Creevy KE, Promislow DE (2016) The dog aging project: translational geroscience in companion animals. Mammalian genome: official journal of the International Mammalian Genome Society 27(7–8):279–288CrossRefGoogle Scholar
Kealy RD et al (2002) Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 220(9):1315–1320CrossRefPubMedGoogle Scholar
Khan KH et al (2016) Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist 21(7):855–860CrossRefPubMedGoogle Scholar
Majumder S et al (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11(2):326–335CrossRefPubMedPubMedCentralGoogle Scholar
Parikh JD, Hollingsworth KG, Wallace D, Blamire AM, MacGowan GA (2016) Normal age-related changes in left ventricular function: role of afterload and subendocardial dysfunction. Int J Cardiol 223:306–312CrossRefPubMedPubMedCentralGoogle Scholar
Pitt JN, Kaeberlein M (2015) Why is aging conserved and what can we do about it? PLoS BiolGoogle Scholar
Ross C et al (2015) Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY) 7(11):964–973CrossRefGoogle Scholar
Singh JP et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83(6):897–902CrossRefPubMedGoogle Scholar
Tardif S et al (2015) Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 70(5):577–587CrossRefPubMedGoogle Scholar
Team RC (2016) R: a language and environment for statistical computing. R foundation for statistical Computing, ViennaGoogle Scholar
Templeton GH, Willerson JT, Platt MR, Weisfeldt M (1976) Contraction duration and diastolic stiffness in aged canine left ventricle. Recent Adv Stud Cardiac Struct Metab 11:169–173PubMedGoogle Scholar
Weinreich J et al (2011) Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling. Eur Surg Res 47(1):39–44CrossRefPubMedGoogle Scholar